First-line therapy in adult Crohn's disease: who should receive anti-TNF agents?

@article{PeyrinBiroulet2013FirstlineTI,
  title={First-line therapy in adult Crohn's disease: who should receive anti-TNF agents?},
  author={L. Peyrin-Biroulet and G. Fiorino and A. Buisson and S. Danese},
  journal={Nature Reviews Gastroenterology \&Hepatology},
  year={2013},
  volume={10},
  pages={345-351}
}
Therapy for Crohn's disease has long been based on a step-up approach, with monoclonal antibodies against TNF as a final option before surgery. Despite the introduction of these monoclonal antibodies, no major changes have occurred in the natural history of Crohn's disease, with half of all patients still requiring intestinal resection at 10 years. Labelling for anti-TNF agents does not take into account prognostic factors. In this Review, we propose that treatment of Crohn's disease be based… Expand

Paper Mentions

Interventional Clinical Trial
Thus, the aim of the current study is to assess the influence of vitamin D deficiency and, consequently, of serum calcium deficiency in the body composition, muscular activity, bone… Expand
ConditionsCrohn Disease, Disorder of Bone Density and Structure, Unspecified, Fatigue, (+3 more)
InterventionDietary Supplement, Other
Treatment algorithms in Crohn's - up, down or something else?
Optimization of biologic therapy in Crohn’s disease
Early Biologic Treatment in Pediatric Crohn's Disease: Catching the Therapeutic Window of Opportunity in Early Disease by Treat-to-Target
  • B. Kang, Y. Choe
  • Medicine
  • Pediatric gastroenterology, hepatology & nutrition
  • 2018
A guide to preparation of patients with inflammatory bowel diseases for anti-TNF-α therapy
Considerations, challenges and future of anti-TNF therapy in treating inflammatory bowel disease
Crohn's disease
Moving towards disease modification in inflammatory bowel disease therapy
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 86 REFERENCES
Advanced age is an independent risk factor for severe infections and mortality in patients given anti-tumor necrosis factor therapy for inflammatory bowel disease.
  • M. Cottone, A. Kohn, +16 authors A. Orlando
  • Medicine
  • Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
  • 2011
Infliximab for the treatment of fistulas in patients with Crohn's disease.
Infliximab maintenance therapy for fistulizing Crohn's disease.
Certolizumab pegol for the treatment of Crohn’s disease
  • S. Schreiber
  • Medicine
  • Therapeutic advances in gastroenterology
  • 2011
...
1
2
3
4
5
...